Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Tricks Wrote:

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Nov 13, 2020 2:10pm

109 Views

Post# 31896366

RE:Tricks Wrote:

Did we hurt your feelings dumpester? Or are you still feeling butt hurt from selling few hundred shares too early? Lmao!

Duster340 wrote: Honestly it's quite entertaining watching him flip flop his opinion. I get a good laugh out of it. (yeah me to i was laughing all the way to the bank with my latest flip flop haha, am i the only one making $$$ on this stock lol )

<< Previous

Bullboard Posts

Next >>

Michael Gentile tops up stake in Astra Exploration